

## ASX ANNOUNCEMENT

ASX: 1AI | 10 December 2025

### Highlights

- **Algorae receives \$384,466.78 cash refund from Australian Taxation Office**
- **Non-dilutive funding strengthens balance sheet and supports AI-driven drug discovery programs and commercial pipeline**

AI-enabled pharmaceutical company **Algorae Pharmaceuticals Ltd (ASX: 1AI)** ('Algorae' or 'the Company') is pleased to advise that it has received a cash refund of **\$384,466.78** from the Australian Taxation Office under the Australian Government's Research & Development ('R&D') Tax Incentive program for eligible R&D activities undertaken during the 2025 financial year.

The refund provides non-dilutive funding that strengthens Algorae's cash position and will be applied to advancing the Company's artificial intelligence-driven drug discovery programs and rapidly expanding commercial pipeline.

Receipt of the R&D Tax Incentive refund reflects Algorae's ongoing investment in innovative AI-based approaches to pharmaceutical development and supports the continued progression of its portfolio of novel drug candidates.

**Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd**

**END.**

### Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: [investors@algoraepharma.com](mailto:investors@algoraepharma.com)

### About Algorae Pharmaceuticals

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical development company pioneering drug synergy discovery and development for unmet medical needs. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations with transformative therapeutic potential. Algorae collaborates with leading research institutions and pharmaceutical partners to accelerate the translation of AI-predicted therapies into the clinic.

Algorae intends to expand its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform. Known as Algorae Operating System (AlgoraeOS), the AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine

learning, deep learning, and neural networks, the aim of AlgoraeOS is to uncover synergistic drug combinations that lead to the development of novel and effective treatments for any medical condition, aligning with Algorae's commitment to address unmet medical needs. Algorae is listed and publicly traded on the Australian Stock Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit [www.algoraeopharma.com](http://www.algoraeopharma.com) or follow @algoraeopharma on X or LinkedIn.

#### **Forward-looking Statements**

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.